Robotic Surgery and Implant Technologies Approved by FDA

  • Globus Medical’s knee arthroplasty device receives U.S. FDA clearance
  • ExcelsiusFlex robotic navigation platform approved for total knee arthroplasty application
  • Actify 3D total knee system also cleared by the FDA
  • Company preparing for commercial release in the near future

Globus Medical, a musculoskeletal solutions company, announced that its ExcelsiusFlex robotic navigation platform has received U.S. Food and Drug Administration (FDA) clearance for total knee arthroplasty application. Additionally, the Actify 3D total knee system, the latest implant technology from Globus Medical, has also been cleared by the FDA. The ExcelsiusFlex device is designed to assist surgeons in primary total knee arthroplasty procedures through robotically-guided resections based on their implant placement planning. With these 510(k) FDA clearances in hand, Globus Medical is now ramping up production and preparing for a commercial release in the near future.

Factuality Level: 9
Factuality Justification: The article provides accurate information about the FDA clearance of Globus Medical’s ExcelsiusFlex robotic navigation platform and Actify 3D total knee system without any sensationalism or irrelevant details. It also includes a direct quote from the company regarding their plans for production and commercial release.
Noise Level: 2
Noise Justification: The article provides relevant information about a company’s FDA clearance for its medical devices without any unnecessary filler content or misleading statements.
Public Companies: Globus Medical (not available)
Key People: Michael Susin (Author)

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: Healthcare industry
Financial Rating Justification: The article discusses FDA clearances for new medical devices, which can impact the financial performance of Globus Medical and potentially affect the healthcare industry as a whole.
Presence Of Extreme Event: No
Nature Of Extreme Event: Other
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no mention of an extreme event in this article. It discusses the FDA clearance for a medical device and its technology.

Reported publicly: www.marketwatch.com